A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 3,652,100 shares of AKBA stock, worth $3.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,652,100
Previous 4,779,383 23.59%
Holding current value
$3.73 Million
Previous $5.93 Million 12.77%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$1.27 - $2.24 $1.43 Million - $2.53 Million
-1,127,283 Reduced 23.59%
3,652,100 $6.68 Million
Q4 2023

Feb 13, 2024

BUY
$0.8 - $1.28 $1.3 Million - $2.08 Million
1,623,956 Added 51.47%
4,779,383 $5.93 Million
Q3 2023

Nov 14, 2023

SELL
$0.87 - $1.84 $152,511 - $322,552
-175,300 Reduced 5.26%
3,155,427 $3.6 Million
Q2 2023

Aug 11, 2023

BUY
$0.51 - $1.43 $506,035 - $1.42 Million
992,227 Added 42.43%
3,330,727 $3.05 Million
Q1 2023

May 12, 2023

SELL
$0.56 - $1.15 $306,727 - $629,886
-547,727 Reduced 18.98%
2,338,500 $1.31 Million
Q4 2022

Feb 13, 2023

SELL
$0.25 - $0.58 $32,550 - $75,516
-130,200 Reduced 4.32%
2,886,227 $1.67 Million
Q3 2022

Nov 14, 2022

BUY
$0.32 - $0.46 $490,920 - $705,698
1,534,127 Added 103.5%
3,016,427 $954,000
Q2 2022

Aug 12, 2022

BUY
$0.32 - $0.67 $153,271 - $320,911
478,973 Added 47.74%
1,482,300 $523,000
Q1 2022

May 13, 2022

BUY
$0.72 - $2.93 $273,816 - $1.11 Million
380,300 Added 61.04%
1,003,327 $720,000
Q4 2021

Feb 11, 2022

SELL
$2.26 - $3.34 $738,793 - $1.09 Million
-326,900 Reduced 34.41%
623,027 $1.41 Million
Q3 2021

Nov 12, 2021

SELL
$2.35 - $3.88 $2.06 Million - $3.41 Million
-877,803 Reduced 48.03%
949,927 $2.74 Million
Q2 2021

Aug 13, 2021

BUY
$2.83 - $4.2 $2.14 Million - $3.18 Million
757,149 Added 70.72%
1,827,730 $6.93 Million
Q1 2021

May 13, 2021

SELL
$2.92 - $5.06 $1.1 Million - $1.91 Million
-377,346 Reduced 26.06%
1,070,581 $3.62 Million
Q4 2020

Feb 10, 2021

BUY
$2.22 - $3.78 $3.06 Million - $5.21 Million
1,377,752 Added 1963.31%
1,447,927 $4.05 Million
Q3 2020

Nov 13, 2020

SELL
$2.39 - $13.08 $13,178 - $72,123
-5,514 Reduced 7.29%
70,175 $176,000
Q2 2020

Aug 13, 2020

BUY
$6.67 - $13.58 $504,845 - $1.03 Million
75,689 New
75,689 $1.03 Million
Q1 2020

May 14, 2020

SELL
$4.1 - $10.24 $567,960 - $1.42 Million
-138,527 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$3.16 - $6.73 $300,516 - $640,023
95,100 Added 218.99%
138,527 $875,000
Q3 2019

Nov 13, 2019

BUY
$3.55 - $5.4 $154,165 - $234,505
43,427 New
43,427 $170,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $188M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.